Literature DB >> 25755319

Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.

Dileep K Atluri1, Ravi Prakash1, Kevin D Mullen1.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric disorder seen in patients with advanced liver disease or porto-systemic shunts. Based on etiology and severity of HE, the World Congress of Gastroenterology has divided HE into categories and sub-categories. Many user-friendly computer-based neuropsychiatric tests are being validated for diagnosing covert HE. Currently, emphasis is being given to view HE deficits as a continuous spectrum rather than distinct stages. Ammonia is believed to play crucial role in pathogenesis of HE via astrocyte swelling and cerebral edema. However, evidence has been building up which supports the synergistic role of oxidative stress, inflammation and neurosteroids in pathogenesis of HE. At present, treatment of HE aims at decreasing the production and intestinal absorption of ammonia. But as the role of new pathogenetic mechanisms becomes clear, many potential new treatment strategies may become available for clinician.

Entities:  

Keywords:  AAA, aromatic amino acid; BAUR, brain ammonia utilization rate; BCAA, branched-chain amino acids; CFF, critical flicker fusion; DBI, diazepam binding inhibitor; DST, digit symbol test; DWI, diffusion weighted imaging; Diagnosis; ECAD, extra-corporeal albumin dialysis; EEC, electroencephalogram; FLAIR, fluid attenuation inversion recovery; HE, hepatic encephalopathy; HESA, hepatic encephalopathy scoring algorithm; ICT, inhibitory control test; IL, interleukin; LOLA, L-ornithine L-aspartate; LTT, line tracing test; MARS, molecular adsorbent reticulating system; MHE, minimal hepatic encephalopathy; MRI, magnetic resonance imaging; NAC, N-acetyl cysteine; NO, nitric oxide; NS, neurosteroids; NSAID, non-steroidal anti-inflammatory drugs; ODN, octadecaneuropeptide; OHE, overt hepatic encephalopathy; PTBR, peripheral-type benzodiaze-pine receptor; QOL, quality of life; SDT, serial dotting test; SEDACA, short epoch, dominant activity, and cluster analysis; SIBO, small intestinal bacterial overgrowth; SIRS, systemic inflammatory response syndrome; SOD, Superoxide dismutase; SONIC, spectrum of neurological impairment; TLP, TransLocator Protein; TNF, tumor necrosis factor; hepatic encephalopathy; pathogenesis; treatment

Year:  2011        PMID: 25755319      PMCID: PMC3940085          DOI: 10.1016/S0973-6883(11)60126-6

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  75 in total

1.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

2.  The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy.

Authors:  Satish Iduru; Kevin D Mullen
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

Review 3.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

4.  Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Authors:  Antoni Mas; Juan Rodés; Lourdes Sunyer; Luís Rodrigo; Ramon Planas; Victor Vargas; Lluís Castells; Dolores Rodríguez-Martínez; Conrado Fernández-Rodríguez; Ignasi Coll; Albert Pardo
Journal:  J Hepatol       Date:  2003-01       Impact factor: 25.083

Review 5.  Pathways and mechanisms for cytokine signaling of the central nervous system.

Authors:  J Licinio; M L Wong
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA).

Authors:  Tarek I Hassanein; Robin C Hilsabeck; William Perry
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

Review 7.  Benzodiazepine receptor antagonists for hepatic encephalopathy.

Authors:  B Als-Nielsen; L L Gluud; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.

Authors:  C Rose; A Michalak; P Pannunzio; G Therrien; G Quack; G Kircheis; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-06       Impact factor: 3.584

Review 9.  Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis.

Authors:  Debbie L Shawcross; Shabnam S Shabbir; Nicholas J Taylor; Robin D Hughes
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

10.  Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

Authors:  E Strauss; R Tramote; E P Silva; W R Caly; N Z Honain; R A Maffei; M F de Sá
Journal:  Hepatogastroenterology       Date:  1992-12
View more
  22 in total

1.  Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight.

Authors:  Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-09

2.  Hepatobiliary quiz-10 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-06

Review 3.  Gut microbiota and hepatic encephalopathy.

Authors:  Radha K Dhiman
Journal:  Metab Brain Dis       Date:  2013-03-06       Impact factor: 3.584

4.  Brain perfusion single photon emission computed tomography abnormalities in patients with minimal hepatic encephalopathy.

Authors:  Hejjaji Venkataramarao Sunil; Bhagwant Rai Mittal; Roshan Kurmi; Yogesh K Chawla; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 5.  Multimodal MR imaging in hepatic encephalopathy: state of the art.

Authors:  Xiao Dong Zhang; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2018-01-26       Impact factor: 3.584

6.  Endogenous Expression of ODN-Related Peptides in Astrocytes Contributes to Cell Protection Against Oxidative Stress: Astrocyte-Neuron Crosstalk Relevance for Neuronal Survival.

Authors:  Ikram Ghouili; Seyma Bahdoudi; Fabrice Morin; Fatma Amri; Yosra Hamdi; Pierre Michael Coly; Marie-Laure Walet-Balieu; Jérôme Leprince; Sami Zekri; Hubert Vaudry; David Vaudry; Hélène Castel; Mohamed Amri; Marie-Christine Tonon; Olfa Masmoudi-Kouki
Journal:  Mol Neurobiol       Date:  2017-07-11       Impact factor: 5.590

Review 7.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  Multimodality magnetic resonance imaging in hepatic encephalopathy: an update.

Authors:  Xiao-Dong Zhang; Long-Jiang Zhang; Sheng-Yong Wu; Guang-Ming Lu
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis.

Authors:  Xiu Wu; Xiao-Fei Lv; Yu-Ling Zhang; Hua-Wang Wu; Pei-Qiang Cai; Ying-Wei Qiu; Xue-Lin Zhang; Gui-Hua Jiang
Journal:  Front Neuroanat       Date:  2015-06-08       Impact factor: 3.856

Review 10.  L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Ee Teng Goh; Caroline S Stokes; Sandeep S Sidhu; Hendrik Vilstrup; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.